Table 2.
In vitro antifungal susceptibility testing of 243 clinical isolates into 5 antifungal agents
| Species (No of isolates) | Antifungal agent | MIC (μg/mL) | % Resistant | ||
|---|---|---|---|---|---|
| Range | 50% | 90% | |||
| Candida albicans (110) | Amphotericin B | ≤0.5 to 1 | ≤0.5 | ≤0.5 | 0b |
| Flucytosine | 0.5 to > 8 | 0.5 | 1 | 5.5b | |
| Fluconazole | ≤0.125 to 32 | 0.25 | 0.5 | 20.0 | |
| Itraconazole | ≤0.062 to 4 | ≤0.062 | 0.5 | 28.2b | |
| Voriconazole | ≤0.062 to > 8 | ≤0.062 | 0.125 | 23.6 | |
| Candida glabrata (73) | Amphotericin B | ≤0.5 to 1 | ≤0.5 | 1 | 0b |
| Flucytosine | ≤0.062 to > 16 | 0.125 | 0.5 | 2.7b | |
| Fluconazole | 0.25 to> 128 | 8 | 32 | 11.0 | |
| Itraconazole | ≤0.25 to > 8 | 2 | 4 | 6.8b | |
| Voriconazole | ≤0.062 to > 8 | 0.25 | 0.5 | 6.8b | |
| Candida tropicalis (37) | Amphotericin B | ≤0.5 to 1 | ≤0.5 | 1 | 0b |
| Flucytosine | ≤0.062 to 4 | 0.125 | 0.125 | 5.4b | |
| Fluconazole | 0.25 to 64 | 1 | 2 | 29.7 | |
| Itraconazole | ≤0.062 to 64 | 0.125 | 0.25 | 40.5b | |
| Voriconazole | ≤0.062 to > 8 | ≤0.062 | 0.125 | 27.0 | |
| Candida krusei (12) | Amphotericin B | ≤0.5 to 2 | ≤0.5 | 1 | 0b |
| Flucytosine | 2 to 8 | 4 | 8 | 0 | |
| Fluconazolea | – | – | – | – | |
| Itraconazole | ≤0.062 to 4 | 0.125 | 0.5 | 33.4b | |
| Voriconazole | ≤0.062 to > 8 | 0.125 | 0.25 | 25.0 | |
| Candida parapsilosis (5) | Amphotericin B | ≤0.5 to 1 | 0.5 | 1 | 0 |
| Flucytosine | ≤0.062 to 0.5 | 0.125 | 0.25 | 0 | |
| Fluconazole | 0.25 to 16 | 0.5 | 2 | 20.0 | |
| Itraconazole | ≤0.062 to 1 | ≤0.062 | 0.125 | 20.0b | |
| Voriconazole | ≤0.062 to 4 | ≤0.062 | 0.125 | 20.0 | |
| Othersc (6) | Amphotericin B | ≤0.5 to 1 | ≤0.5 | 1 | 0b |
| Flucytosine | ≤0.062 to 1 | 0.25 | 1 | 0b | |
| Fluconazole | 0.5 to 64 | 1 | 4 | 16.7b | |
| Itraconazole | ≤0.062 to 0.125 | ≤0.062 | 0.125 | 0b | |
| Voriconazole | ≤0.062 to 0.5 | ≤0.062 | 0.125 | 0b | |
| All of isolates (243) | Amphotericin B | – | – | – | 0 |
| Flucytosine | – | – | – | 4.1 | |
| Fluconazolea | – | – | – | 18.6 | |
| Itraconazole | – | – | – | 23.1 | |
| Voriconazole | – | – | – | 18.5 | |
MIC minimal inhibitory concentration
aResistance rate was based on the intrinsic resistance of C. krusei and did not follow the actual MICs
bThe breakpoints of Candida spp. according to the manufacturer’s instructions of ATB FUNGUS 3 system
cOthers include C. guilliermondii (3), C. haemulonii (2) and C. pseudotropicalis (1)